Dynamics in Post-pandemic Global Influenzavirus B Infection Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Influenzavirus B Infection Drug Market Status and Forecast (2016-2027)
  • 1.3.2 Global Influenzavirus B Infection Drug Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Influenzavirus B Infection Drug Supply by Company

• 2.1 Global Influenzavirus B Infection Drug Sales Volume by Company
• 2.2 Global Influenzavirus B Infection Drug Sales Value by Company
• 2.3 Global Influenzavirus B Infection Drug Price by Company
• 2.4 Influenzavirus B Infection Drug Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional Influenzavirus B Infection Drug Market Status by Category

• 3.1 Influenzavirus B Infection Drug Category Introduction
  • 3.1.1 APP-309
  • 3.1.2 CF-403
  • 3.1.3 GC-3106A
  • 3.1.4 KIN-1400
  • 3.1.5 Others
• 3.2 Global Influenzavirus B Infection Drug Market by Category
  • 3.2.1 Global Influenzavirus B Infection Drug Sales Volume by Category (2016-2021)
  • 3.2.2 Global Influenzavirus B Infection Drug Sales Value by Category (2016-2021)
  • 3.2.3 Global Influenzavirus B Infection Drug Price by Category (2016-2021)
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Influenzavirus B Infection Drug Market Status by End User/Segment

• 4.1 Influenzavirus B Infection Drug Segment by End User/Segment
  • 4.1.1 Clinic
  • 4.1.2 Hospital
  • 4.1.3 Others
• 4.2 Global Influenzavirus B Infection Drug Market by End User/Segment
  • 4.2.1 Global Influenzavirus B Infection Drug Sales Volume by End User/Segment (2016-2021)
  • 4.2.2 Global Influenzavirus B Infection Drug Sales Value by End User/Segment (2016-2021)
  • 4.2.3 Global Influenzavirus B Infection Drug Price by End User/Segment (2016-2021)
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Influenzavirus B Infection Drug Market Status by Region

• 5.1 Global Influenzavirus B Infection Drug Market by Region
  • 5.1.1 Global Influenzavirus B Infection Drug Sales Volume by Region
  • 5.1.2 Global Influenzavirus B Infection Drug Sales Value by Region
• 5.2 North America Influenzavirus B Infection Drug Market Status
• 5.3 Europe Influenzavirus B Infection Drug Market Status
• 5.4 Asia Pacific Influenzavirus B Infection Drug Market Status
• 5.5 Central & South America Influenzavirus B Infection Drug Market Status
• 5.6 Middle East & Africa Influenzavirus B Infection Drug Market Status

6 North America Influenzavirus B Infection Drug Market Status

• 6.1 North America Influenzavirus B Infection Drug Market by Country
  • 6.1.1 North America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
  • 6.1.2 North America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Influenzavirus B Infection Drug Market Status

• 7.1 Europe Influenzavirus B Infection Drug Market by Country
  • 7.1.1 Europe Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
  • 7.1.2 Europe Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Influenzavirus B Infection Drug Market Status

• 8.1 Asia Pacific Influenzavirus B Infection Drug Market by Country
  • 8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
  • 8.1.2 Asia Pacific Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Influenzavirus B Infection Drug Market Status

• 9.1 Central & South America Influenzavirus B Infection Drug Market by Country
  • 9.1.1 Central & South America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
  • 9.1.2 Central & South America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Influenzavirus B Infection Drug Market Status

• 10.1 Middle East & Africa Influenzavirus B Infection Drug Market by Country
  • 10.1.1 Middle East & Africa Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
  • 10.1.2 Middle East & Africa Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 Influenzavirus B Infection Drug Manufacturing Cost Analysis
• 11.5 Influenzavirus B Infection Drug Sales Channel and Distributors Analysis
  • 11.5.1 Influenzavirus B Infection Drug Sales Channel
  • 11.5.2 Influenzavirus B Infection Drug Distributors
• 11.6 Influenzavirus B Infection Drug Downstream Major Buyers

12 Global Influenzavirus B Infection Drug Market Forecast by Category and by End User/Segment

• 12.1 Global Influenzavirus B Infection Drug Sales Volume and Sales Value Forecast (2022-2027)
• 12.2 Global Influenzavirus B Infection Drug Forecast by Category
  • 12.2.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Category
  • 12.2.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Category
  • 12.2.3 Global Influenzavirus B Infection Drug Price Forecast by Category
• 12.3 Global Influenzavirus B Infection Drug Forecast by End User/Segment
  • 12.3.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by End User/Segment
  • 12.3.2 Global Influenzavirus B Infection Drug Sales Value Forecast by End User/Segment
  • 12.3.3 Global Influenzavirus B Infection Drug Price Forecast by End User/Segment

13 Global Influenzavirus B Infection Drug Market Forecast by Region/Country

• 13.1 Global Influenzavirus B Infection Drug Market Forecast by Region (2022-2027)
  • 13.1.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Region (2022-2027)
  • 13.1.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Vectura Group Plc
  • 14.1.1 Company Information
  • 14.1.2 Influenzavirus B Infection Drug Product Introduction
  • 14.1.3 Vectura Group Plc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Vaxart Inc
  • 14.2.1 Company Information
  • 14.2.2 Influenzavirus B Infection Drug Product Introduction
  • 14.2.3 Vaxart Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 TSRL Inc
  • 14.3.1 Company Information
  • 14.3.2 Influenzavirus B Infection Drug Product Introduction
  • 14.3.3 TSRL Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 SK Chemicals Co Ltd
  • 14.4.1 Company Information
  • 14.4.2 Influenzavirus B Infection Drug Product Introduction
  • 14.4.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Shionogi & Co Ltd
  • 14.5.1 Company Information
  • 14.5.2 Influenzavirus B Infection Drug Product Introduction
  • 14.5.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Sanofi
  • 14.6.1 Company Information
  • 14.6.2 Influenzavirus B Infection Drug Product Introduction
  • 14.6.3 Sanofi Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Sanofi Pasteur SA
  • 14.7.1 Company Information
  • 14.7.2 Influenzavirus B Infection Drug Product Introduction
  • 14.7.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Romark Laboratories LC
  • 14.8.1 Company Information
  • 14.8.2 Influenzavirus B Infection Drug Product Introduction
  • 14.8.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Park Active Molecules
  • 14.9.1 Company Information
  • 14.9.2 Influenzavirus B Infection Drug Product Introduction
  • 14.9.3 Park Active Molecules Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Novavax Inc
  • 14.10.1 Company Information
  • 14.10.2 Influenzavirus B Infection Drug Product Introduction
  • 14.10.3 Novavax Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Mucosis BV
• 14.12 MedImmune LLC
• 14.13 Medicago Inc
• 14.14 Kineta Inc
• 14.15 Inovio Pharmaceuticals Inc
• 14.16 Green Cross Corp
• 14.17 GlaxoSmithKline Plc
• 14.18 Fujifilm Holdings Corporation
• 14.19 Daiichi Sankyo Company Ltd
• 14.20 ContraFect Corp
• 14.21 Cadila Healthcare Ltd
• 14.22 BioCryst Pharmaceuticals Inc
• 14.23 Aphios Corp
• 14.24 Amarillo Biosciences Inc
• 14.25 Altravax Inc
• 14.26 Adimmune Corp
• 14.27 AbbVie Inc

15 Conclusion

16 Methodology